Biological sex disparity in survival outcomes following treatment for renal cell carcinoma: a systematic review protocol.
Journal
JBI evidence synthesis
ISSN: 2689-8381
Titre abrégé: JBI Evid Synth
Pays: United States
ID NLM: 101764819
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
pubmed:
15
7
2021
medline:
2
2
2022
entrez:
14
7
2021
Statut:
ppublish
Résumé
This systematic review will assess the biological sex disparity in survival outcomes following treatment for renal cell carcinoma and analyze the estimates of biological sex disparity outcomes following supposed or proposed curative treatment. Renal cell carcinoma is a type of kidney cancer. There is a lack of conformity in the literature on the biological sex disparity in survival outcomes after treatment. This review will help inform the decision-making of clinicians, health care administrators, policy makers, public health workers, and pharmaceutical/biotechnology researchers in predicting positive outcomes following treatment. The review will consider prospective and retrospective studies on any form of treatment for renal cell carcinoma. The Cox proportional hazard assumption will be used to conduct survival analysis. Hazard rates of participants' survivability across biological sex will also be reported. A three-step search strategy will be used. First, a limited search of MEDLINE, Embase, and PsycINFO was conducted and text words in the title, abstract, and index terms were analyzed. Second, a search using identified keywords and index terms will be tailored for all included databases. Third, the reference lists of all included reports and articles will be screened to search for additional studies. There will be no language or date restrictions. Papers not written in English but with a professional translated copy will be included. Study screening, critical appraisal, and data extraction will be conducted independently by pairs of reviewers. Data synthesis will include narrative review and meta-analysis, if appropriate. PROSPERO CRD42020195721.
Identifiants
pubmed: 34261092
doi: 10.11124/JBIES-20-00277
pii: 02174543-202112000-00012
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3355-3362Informations de copyright
Copyright © 2021 JBI.
Déclaration de conflit d'intérêts
The author declare no conflicts of interest.
Références
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: Cancer J Clin 2019;69 (1):7–34.
Rossi SH, Klatte T, Usher-Smith J, Stewart GD. Epidemiology and screening for renal cancer. World J Urol 2018;36 (9):1341–1353.
Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, et al. Epidemiology of renal cell carcinoma. Eur Urol 2019;75 (1):74–84.
King SC, Pollack LA, Li J, King JB, Master VA. Continued increase in incidence of renal cell carcinoma, especially in young patients and high grade disease: United States 2001 to 2010. J Urol 2014;191 (6):1665–1670.
van Oostenbrugge TJ, Fütterer JJ, Mulders PFA. Diagnostic imaging for solid renal tumors: a pictorial review. Kidney Cancer 2018;2 (2):79–93.
Karakiewicz PI, Jeldres C, Suardi N, Hutterer GC, Perrotte P, Capitanio U, et al. Age at diagnosis is a determinant factor of renal cell carcinoma-specific survival in patients treated with nephrectomy. Can Urol Assoc J 2008;2 (6):610–617.
Eggener SE, Rubenstein JN, Smith ND, Nadler RB, Kontak J, Flanigan RC, et al. Renal tumors in young adults. J Urol 2004;171 (1):106–110.
Chow W-H, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol 2010;7 (5):245–257.
Lee JE, Hankinson SE, Cho E. Reproductive factors and risk of renal cell cancer: the nurses’ health study. Am J Epidemiol 2009;169 (10):1243–1250.
Antwi SO, Eckel-Passow JE, Diehl ND, Serie DJ, Custer KM, Arnold ML, et al. Coffee consumption and risk of renal cell carcinoma. Cancer Cause Control 2017;28 (8):857–866.
Shivappa N, Blair CK, Prizment AE, Jacobs DR Jr, Hébert JR. Dietary inflammatory index and risk of renal cancer in the Iowa Women's Health Study. Eur J Nutr 2018;57 (3):1207–1213.
Shariat SF, Sfakianos JP, Droller MJ, Karakiewicz PI, Meryn S, Bochner BH. The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int 2010;105 (3):300–308.
Stafford HS, Saltzstein SL, Shimasaki S, Sanders C, Downs TM, Sadler GR. Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival. J Urol 2008;179 (5):1704–1708.
Muglia VF, Prando A. Renal cell carcinoma: histological classification and correlation with imaging findings. Radiol Bras 2015;48 (3):166–174.
Lee S, Jeon HG, Kwak C, Kim HH, Byun SS, Lee SE, et al. Gender-specific clinicopathological features and survival in patients with renal cell carcinoma (RCC). BJU Int 2012;110 (2 Pt 2):E28–E33.
May M, Aziz A, Zigeuner R, Chromecki T, Cindolo L, Schips L, et al. Gender differences in clinicopathological features and survival in surgically treated patients with renal cell carcinoma: an analysis of the multicenter CORONA database. World J Urol 2013;31 (5):1073–1080.
Rampersaud EN, Klatte T, Bass G, Patard J-J. The effect of gender and age on kidney cancer survival: younger age is an independent prognostic factor in women with renal cell carcinoma. Urol Oncol 2014;32 (1):30.e39–13.
Schrader AJ, Sevinc S, Olbert PJ, Hegele A, Varga Z, Hofmann R. [Gender-specific characteristics and survival of renal cell carcinoma]. Urologe A. 2008; 47(9):1182, 1184–1186. German.
Beisland C, Medby PC, Beisland HO. Renal cell carcinoma: gender difference in incidental detection and cancer-specific survival. Scand J Urol Nephrol 2002;36 (6):414–418.
Russo P, Jang TL, Pettus JA, Huang WC, Eggener SE, O’Brien MF, et al. Survival rates after resection for localized kidney cancer: 1989 to 2004. Cancer 2008;113 (1):84–96.
Sakai I, Miyake H, Muramaki M, Kondo Y, Kusuda Y, Yamada Y, et al. Significant impact of age at diagnosis on the prognosis of Japanese patients with pT1 renal cell carcinoma following surgical resection. BJU Int 2012;109 (5):695–699.
Scoll BJ, Wong Y-N, Egleston BL, Kunkle DA, Saad IR, Uzzo RG. Age, tumor size and relative survival of patients with localized renal cell carcinoma: a surveillance, epidemiology and end results analysis. J Urol 2009;181 (2):506–511.
Brighi N, Farolfi A, Conteduca V, Gurioli G, Gargiulo S, Gallà V, et al. The interplay between inflammation, anti-angiogenic agents, and immune checkpoint inhibitors: perspectives for renal cell cancer treatment. Cancers (Basel) 2019;11 (12):1935.
Greef B, Eisen T. Medical treatment of renal cancer: new horizons. Br J Cancer 2016;115 (5):505–516.
Krabbe L-M, Bagrodia A, Margulis V, Wood CG. Surgical management of renal cell carcinoma. Semin Intervent Radiol 2014;31 (1):27–32.
Moola S, Munn Z, Tufanaru C, Aromatoris E, Sears K, Sfetcu R. Aromataris E, Munn Z, et al. Chapter 7: systematic reviews of etiology and risk. JBI, JBI Manual for Evidence Synthesis [internet]. Adelaide:2020.
Rathbone J, Hoffmann T, Glasziou P. Faster title and abstract screening? Evaluating Abstrackr, a semi-automated online screening program for systematic reviewers. Syst Rev 2015;4:80–180.
Munn Z, Aromataris E, Tufanaru C, Stern C, Porritt K, Farrow J. The development of software to support multiple systematic review types: the Joanna Briggs Institute System for the Unified Management, Assessment and Review of Information (JBI SUMARI). Int J Evid Based Healthc 2019;17 (1):36–43.
Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ 2009;339:b2535.
Viechtbauer W. Conducting meta-analyses in R with the Metafor package. J Stat Sofw 2010;36 (3):1–48.
Tufanaru C, Munn Z, Stephenson M, Aromataris E. Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness. Int J Evid Based Healthc 2015;13 (3):196–207.
Schünemann H, Brożek J, Guyatt G, Oxman A, editors. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. Updated October 2013. The GRADE Working Group. [internet]. 2013 [cited 2020 May 15]. Available from: https://gdt.gradepro.org/app/handbook/handbook.html.